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Abstract
Count data and recurrent events in clinical trials, such as the number of le-
sions in magnetic resonance imaging in multiple sclerosis, the number of relapses in
multiple sclerosis, the number of hospitalizations in heart failure, and the number
of exacerbations in asthma or in chronic obstructive pulmonary disease (COPD)
are often modeled by negative binomial distributions. In this manuscript we study
planning and analyzing clinical trials with group sequential designs for negative
binomial outcomes. We propose a group sequential testing procedure for negative
binomial outcomes based on Wald statistics using maximum likelihood estimators.
The asymptotic distribution of the proposed group sequential tests statistics are
derived. The finite sample size properties of the proposed group sequential test for
negative binomial outcomes and the methods for planning the respective clinical
trials are assessed in a simulation study. The simulation scenarios are motivated
by clinical trials in chronic heart failure and relapsing multiple sclerosis, which
cover a wide range of practically relevant settings. Our research assures that the
asymptotic normal theory of group sequential designs can be applied to negative
binomial outcomes when the hypotheses are tested using Wald statistics and maxi-
mum likelihood estimators. We also propose two methods, one based on Student’s
t-distribution and one based on resampling, to improve type I error rate control in
small samples. The statistical methods studied in this manuscript are implemented
in the R package gscounts, which is available for download on the Comprehensive
R Archive Network (CRAN).
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1 Introduction
Group sequential clinical trial designs provide a statistical framework for stopping the
clinical trial early for efficacy or futility by testing the hypothesis of interest repeatedly
after groups of new observations are available. Due to the repeated testing, hypothesis
tests in group sequential designs have to be chosen such that they avoid type I error rate
inflation. Usually, the same type of test statistics are used as for the fixed sample designs,
but critical values are altered to control the type I error rate. Group sequential testing
is simplified when the joint distribution of stagewise test statistics is canonical. [2] This is
equivalent to the statement that the stagewise score statistics of the accumulating data
have independent increments. The canonical joint distribution reduces the computational
effort for the calculation of the critical values and, moreover, the theory of group sequen-
tial designs is well established for test statistics following the canonical joint distribution.
However, violations of the independent increment assumption can lead to deviations of
the type I error rate from the target as demonstrated by Shoben and Emerson for longitu-
dinal data analyses based on generalized estimating equations. [1] For a detailed discussion
of group sequential designs, we refer to the comprehensive discourses by Jennison and
Turnbull, by Whitehead, and by Wassmer and Brannath. [2–4]
Counts and recurrent events are common in clinical trials. Examples include the
number of magnetic resonance imaging (MRI) lesions and relapses in relapsing multiple
sclerosis, the number of exacerbations in chronic obstructive pulmonary disease (COPD)
and asthma, the monthly number of migraine days following atrial septal defect closure,
the number of flares in acute gouty arthritis, and the number of hospitalizations in chronic
heart failure. [5–11] However, for group sequential designs with count and recurrent event
endpoints, the literature is sparse and the methods are currently not implemented in
standard software for group sequential designs such as Eastr and ADDPLANr. The ex-
isting literature on group sequential designs with count and recurrent event data includes
models such as nonparametric models, Poisson distribution, and Poisson processes with
frailty. [13,12,14–16] The main focus of the available literature regarding group sequential
designs with recurrent events is on nonparametric and semiparametric models where the
score statistics do not fulfill the independent increment structure.
In this manuscript we focus on group sequential designs with recurrent events modeled
by a negative binomial distribution which is commonly considered to model endpoints in
clinical trials in multiple sclerosis, chronic heart failure, asthma, and COPD. [5–8,11] We
propose a group sequential Wald test which follows the canonical joint distribution asymp-
totically. The finite sample size performance of the test are assessed by means of a Monte
Carlo simulation study with scenarios motivated by clinical trial examples. Since the
canonical joint distribution only holds asymptotically, particular emphasis is put on the
performance of the proposed group sequential test for the case of small sample sizes and
methods for controlling the type I error are discussed. Moreover, we propose methods for
planning clinical trials with a group sequential design and negative binomial outcomes.
The information level for negative binomial outcomes depends not only on the sample size
but also on the overdispersion parameter, the event rates, and the individual follow-up
times. This provides considerable flexibility when designing a group sequential trial with
negative binomial outcomes, which we discuss in detail in this manuscript.
The remainder of this manuscript is structured as follows. In Section 2 we discuss
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the number of hospitalizations in heart failure trials and the number of MRI lesions in
relapsing-remitting multiple sclerosis trials as motivating examples for negative binomial
outcomes in clinical trials. In Section 3 methods for analyzing group sequential designs
with negative binomial outcomes are established and the respective planning aspects are
discussed in Section 4. The operating characteristics of the methods for analyzing and
planning group sequential designs with negative binomial outcomes are assessed by Monte
Carlo simulation studies in Section 5. In Section 6 we propose ad hoc modifications of the
Wald test to achieve type I error control in the case of small sample sizes. The examples
are revisited in Section 7. A discussion of the results and of future research is provided
in Section 8.
2 Clinical trial examples
In this section we discuss two examples of clinical trials in which the endpoint is commonly
modeled by a negative binomial distribution. Later on in this manuscript we will motivate
the simulation scenarios using the examples introduced in this section. The examples cover
a wide variety of clinical trial scenarios with respect to study duration, follow-up time,
and study phase.
2.1 Chronic heart failure
Chronic heart failure describes a medical condition in which a patient’s blood flow or blood
pressure is reduced. There are three variants of this condition: heart failure with reduced
ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), and
heart failure with preserved ejection fraction (HFpEF). [17] Ejection fraction is the ratio
of the amount of blood pumped out of the heart and the amount of blood in the heart
chamber. In clinical trials in heart failure the main treatment goals include the reduction
of mortality and the number of heart failure hospitalizations. [18] In particular when the
cardiovascular mortality is low, heart failure hospitalizations are an important endpoint
for characterizing the efficacy of a treatment as well as the burden for patients and the
health care system. Recently, the negative binomial distribution has been proposed as
one model for heart failure hospitalizations in clinical trials in heart failure. [19,11,20] In the
following we focus on heart failure hospitalizations in clinical trials in HFpEF. For more
information on HFpEF we refer to the literature. [21,22] The CHARM-Preserved trial is a
double-blind, multi-center, placebo-controlled phase 3 clinical trial which assessed the ef-
ficacy of candesartan in patients with HFpEF. [23] A total of 3023 patients were randomly
assigned to either candesartan (1514 patients) or placebo (1509 patients); the median
follow-up time was 36.6 months. The heart failure hospitalizations observed during the
CHARM-Preserved trial are listed in Table 1.
Using the negative binomial distribution, the rate ratio for recurrent heart failure hospi-
talizations is estimated to be θˆ = 0.71. [11]
In general, adaptive trial designs have been recommended as one potential design for
increasing the effectiveness of clinical trials for cardiovascular diseases. [24,25]
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Table 1: Heart failure hospitalizations in the CHARM-Preserved trial. [23]
Placebo Candesartan
Number of patients 1509 1514
Total follow-up years 4374.03 4424.62
Patients with ≥ 1 admission 278 230
Total admissions 547 392
2.2 Relapsing-remitting multiple sclerosis
Relapsing-remitting multiple sclerosis is a form of multiple sclerosis which is characterized
by sudden worsenings of the symptoms, relapses, followed by a remission period with no
or only few symptoms. The therapeutic goal for relapsing-remitting multiple sclerosis
is the prevention of disease progression, i.e., the prevention of relapses and worsening
of disabilities. However, in particular in early phases, the number of lesions, measured
through magnetic resonance imaging (MRI), is chosen as an endpoint instead of the
number of relapses. This is due to the number of MRI lesions generally being more
sensitive to disease activity and progression which is associated with a smaller required
sample size in clinical trials. More precisely, the disease activity is often measured through
the number of new gadolinium-enhancing lesions on T1-weighted images or through the
number of new or enlarged lesions on T2-weighted images. It is also possible to combine
both types of lesions which is then referred to as the number of combined unique active
MRI lesions (CUALs). For a broader discussion of this topic, see Cohen and Rudick. [27]
Selmaj et al. reported an adaptive, dose-ranging, randomized phase 2 study assessing the
dose-response relationship of siponimod (the BOLD study). [28] The primary endpoint was
the dose-response relationship assessed considering the number of CUALs. Table 2 lists
the monthly number of CUALs at 3 months for placebo and two of the five doses from
the BOLD study. The dosage of 0.25 mg per day was the smallest dose and 2 mg per day
the dosage after which only a small gain in efficacy was observed.
Table 2: Monthly number of CUALs (at 3 months) reported in the BOLD study. [28]
Placebo Siponimod 0.25 mg Siponimod 2 mg
Number of patients 61 51 45
Monthly CUALs 1.39 0.78 0.42
Lesion ratio to placebo - 0.557 0.303
The number of combined unique active lesions was analyzed using a negative binomial
model. Moreover, it is worthwhile to mention that the study consisted of two patient
cohorts of which cohort one was considered for an interim analysis and for selecting
additional doses for the second cohort.
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3 Analyzing group sequential designs with negative
binomial outcomes
In this section we introduce the statistical model and propose a Wald test for analyzing
group sequential designs with negative binomial outcomes.
3.1 Statistical model, hypotheses, and notation
We define K as the maximum number of data looks or analyses, that is the maximum
number of times the hypotheses of interest can be tested throughout the conduct of the
clinical trial. For instance, a design with K = 3 data looks has two interim analyses
and one final analysis if the trial is not stopped early. We model the number of events
of patient j = 1, . . . , ni in treatment group i = 1, 2 at data look k = 1, . . . , K as a
homogeneous Poisson point process with rate λij . Let tijk be the exposure time of patient
j in treatment group i at look k. After an exposure time of tijk, the number of events Yijk
of patient j in treatment group i at data look k given the rate λij is Poisson distributed
with rate tijkλij, that is
Yijk|λij ∼ Pois(tijkλij).
The between patient heterogeneity of the event rates is modeled by assuming that the
subject specific event rates λij are Gamma distributed. The Gamma distribution of λij
has a shape α = 1/φ and rate β = 1/(φµi), i.e.,
λij ∼ Γ
(
1
φ
,
1
φµi
)
.
Then, the random variable Yijk is marginally negative binomial distributed with rate tijkµi
and shape parameter φ, i.e.,
Yijk ∼ NB (tijkµi, φ) .
For y ∈ N0, the probability mass function of Yijk is given by
P (Yijk = y) =
Γ(y + 1/φ)
Γ(1/φ)y!
(
1
1 + φtijkµi
)1/φ (
φtijkµi
1 + φtijkµi
)y
.
The expected value and the variance of the random variable Yijk are given by
E [Yijk] = tijkµi and Var [Yijk] = tijkµi(1 + φtijkµi).
As the shape parameter approaches zero, the negative binomial distribution converges
to a Poisson distribution. While a Poisson process has independent, Poisson distributed
increments, [29] a negative binomial counting process only has conditionally independent
increments, i.e., (Yijk−Yij(k−1))|λij (k = 2, . . . , K) are Poisson distributed with rate (tijk−
tij(k−1))λij. Marginally, the increments are negative binomial distributed and dependent
with the covariance
Cov
[
Yij(k−1), Yijk − Yij(k−1)
]
= tijk(tijk − tij(k−1))φµ2i .
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In this manuscript we consider smaller values of µi to be better. The statistical
hypothesis testing problem of interest is
H0 :
µ1
µ2
≥ δ vs. H1 : µ1
µ2
< δ.
For δ ∈ (1,∞) non-inferiority of treatment 1 compared to treatment 2 is tested and for
δ ∈ (0, 1] superiority of treatment 1 compared to treatment 2 is tested. We denote the
rate ratio as θ = µ1/µ2. Let the log-rate be βi = log(µi).
3.2 Maximum likelihood estimators and Wald statistics
In the following we discuss the Wald test for the hypothesis H0 at data look k = 1, . . . , K.
Let βˆik be the maximum likelihood estimator of the log-rate βi and φˆk be the maximum
likelihood estimator of the shape parameter φ based on the data available at data look
k. Then, the maximum likelihood estimator for the rate µi at data look k is given by
µˆik = exp(βˆik). The maximum likelihood estimator (βˆ1k, βˆ2k, φˆk) at data look k is obtained
by maximizing the likelihood function
L(β1, β2, φ|Yijk = yijk, j = 1, . . . , ni, i = 1, 2) =
2∏
i=1
ni∏
j=1
P (Yijk = yijk) .
The counts observed at previous looks do not have to be considered in the likelihood
since the random variables Yijk (j = 1, . . . , ni, i = 1, 2) are sufficient for the parameter
vector (β1, β2, φ) at data look k. As a reviewer pointed out, it follows from basic proper-
ties of the Poisson distribution that the distribution of Yij1, . . . , Yij(k−1)|Yijk, λij does not
depend on the subject specific event rate λij and, consequently, the marginal distribution
Yij1, . . . , Yij(k−1)|Yijk also does not depend on λij either. Details about the sufficiency of
Yijk at data look k and the calculation of the maximum likelihood estimators are pre-
sented in Appendix A. It should be noted that no closed form expression is available
for the maximum likelihood estimators with negative binomially distributed endpoints.
Moreover, the maximum likelihood rate estimator is not identical to the method of mo-
ments rate estimator which estimates a rate by the ratio of total events and total exposure
time. They are only identical if the exposure times within a treatment arm are identical.
The Fisher information of the parameter βi at data look k is given by
I
(k)
βi
=
ni∑
j=1
tijk exp(βi)
1 + φtijk exp(βi)
=
ni∑
j=1
tijkµi
1 + φtijkµi
.
The expected Fisher information is a special case of the expected Fisher information of the
log-rates in a negative binomial regression model. [30] The larger the Fisher information, the
smaller the uncertainty and the larger the knowledge about the parameter βi. The Fisher
information increases as the shape parameter decreases, the sample size ni increases, or
the exposure time tijk increases.
The Wald statistic for testing the hypothesis H0 at data look k = 1, . . . , K is based
on the difference of log-rates, i.e., βˆ1k − βˆ2k. Let the information level at data look k be
Ik = 11
I
(k)
β1
+ 1
I
(k)
β2
=
I
(k)
β1
I
(k)
β2
I
(k)
β1
+ I(k)β2
. (1)
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Analogously to the Fisher information, the information level measures the knowledge
available about the difference of the log-rates. The effect of shape parameter, sample size,
and exposure time on the information level are as described above. The differences of
log-rates is asymptotically normally distributed, i.e.,
(
βˆ1k − βˆ2k − (β1 − β2)
)√
Ik
[
n→∞]D∼N (0, 1) .
The asymptotic normality of the differences of log-rates follows from the asymptotic nor-
mality of the vector (βˆ1k, βˆ2k, φˆ) shown by Lawless (1987). [30] The information level Ik
depends on the shape parameter φ as well as the true, unknown rates. To construct a test
statistic for H0 using the asymptotic normality of the difference of log-rates, we replace
the information level Ik by a consistent estimator Iˆk and obtain the Wald statistic at
data look k as
Tk =
(
βˆ1k − βˆ2k − log(δ)
)√
Iˆk.
Since we estimate the information level by a consistent estimator, the Wald statistic Tk is
still asymptotically normally distributed under the null hypothesis due to Slutsky’s the-
orem. Under the alternative hypothesis, the Wald statistic Tk is approximately normally
distribution, i.e.,
Tk ∼ N (β1 − β2 − log(δ), 1) = N (log(θ/δ), 1) . (2)
A consistent estimator Iˆk for the information level Ik is obtained by plugging in the
maximum likelihood rate and shape estimators into (1). The hypothesis H0 is rejected
if Tk is smaller than or equal to the critical value ck for any k = 1, . . . , K. In the next
subsection we discuss the calculation of the critical values ck.
3.3 Group sequential testing
In the following we recapitulate the general idea of group sequential testing and discuss
how the canonical joint distribution applies to the Wald test defined above. We focus on
calculating the critical values for group sequential designs which allow stopping for efficacy.
In practice it is very common to also include futility stopping boundaries. However,
these are almost always treated as non-binding such that they do not affect the efficacy
stopping boundaries. [31] A design with stopping for efficacy is discontinued at data look
k = 1, . . . , K−1 if the null hypothesis H0 can be rejected. If the null hypothesis H0 cannot
be rejected at data look k = 1, . . . , K − 1, the study is continued. While the efficacy
stopping boundaries are calculated in this way, it is advisable to also carefully consider
non-binding futility stopping rules, in particular with respect to their impact on operating
characteristics such as power, sample size, trial duration etc. Furthermore, a failure to
specify futility rules during the planning stage might result in the usage of inappropriate
ad-hoc futility rules with undesired or suboptimal operation characteristics. Therefore,
we examine non-binding futility boundaries in Section 4 when discussing planning a group
sequential design with negative binomial outcomes.
A group sequential test for efficacy controls the type I error rate α if the critical values
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c1, . . . , cK are chosen such that the probability to incorrectly reject the null hypothesis at
one of the data looks is equal to α:
α = PH0 (Tk ≤ ck for some k = 1, . . . , K) .
To obtain a solution, the global type I error rate α is split into K local type I error rates
pik, k = 1, . . . , K, such that the local type I error rates sum up to α, i.e.,
∑
k pik = α.
Then, the critical values ck, k = 1, . . . , K, are successively calculated such that
PH0 (T1 > c1, . . . , Tk−1 > ck−1, Tk ≤ ck) = pik. (3)
For calculating the critical value ck the joint distribution of test statistics T1, . . . , Tk under
the null hypothesis H0 must be known. The vector of Wald statistics (T1, . . . , Tk) follows
at the boundary ∂H0 asymptotically a multivariate normal distribution with mean vector
0 ∈ Rk and k×k-dimensional covariance matrix Σk which (k1, k2)-th and (k2, k1)-th entries
are given by √Ik1
Ik2
, 1 ≤ k1 ≤ k2 ≤ K. (4)
Here, Ik is the information level at look k. This type of distribution is often referred to
as the canonical joint distribution. [2] The asymptotic joint distribution of the sequence of
test statistics follows from the more general result that the canonical joint distribution
is the limiting distribution of a sequence of semiparametric efficient test statistics in a
semiparametric model. [32] This class of models and test statistics includes parametric
models and Wald statistics, see the remark on page 1344 in Scharfstein et al. (1997). [32]
The negative binomial model introduced above fulfills this requirement since the random
variables Yijk with j = 1, . . . , ni and i = 1, 2 are sufficient for the parameter vector
(β1, β2, φ) at data look k. Thus, the sequence of Wald statistics in the negative binomial
model converges in distribution to the canonical joint distribution. It is worth highlighting
that the asymptotic joint distribution of the sequence of Wald statistics in the negative
binomial model also follows from arguments made by Jennison and Turnbull (1997) in their
discussion. [33] The asymptotic joint distribution is obtained even though the number of
events of a patient at disjunct time periods is dependent. It is important to emphasize that
estimating the log rates in the Wald statistics with the maximum likelihood estimators
and not with the method of moments estimators is mandatory to obtain asymptotically
the canonical joint distribution. With the sequence of Wald statistics asymptotically
following the joint canonical distribution, the critical value ck is calculated by solving
(3) under the assumption of asymptotic normality. For k = 1, the critical value is the
pi1-quantile of a standard normal distribution, i.e., c1 = qpi1 .
It remains to discuss how to determine the data look specific type I error rates pik. The
most common method for allocating the global type I error rate α is the error spending
approach. [34] An error spending function is a non-decreasing function f : [0,∞) → [0, α]
with f(0) = 0 and f(t) = α for t ≥ 1. Then, the type I error rate pik allocated to data
look k = 1, 2, . . . , K is defined by
pi1 = f (I1/Imax) ,
pik = f (Ik/Imax)− f (Ik−1/Imax) k = 2, 3, . . . , K.
Here, Imax denotes the prespecified maximum information level at which the final data
look is performed if the trial is not stopped early for efficacy.
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3.4 Determining the critical values
To calculate the critical value ck, the canonical joint distribution of the Wald statistics
and the allocated type I error rate pik must be known. Both depend on the information
levels I1, . . . , Ik. When the data looks are performed at information levels specified prior
to the trial, the critical values can be determined prior to the trial, too. Then, the
main issue is to monitor the information level of the clinical trial. Here, we focus on the
scenario where the information levels of the data looks are not specified before the trial
and can differ from the pre-planned information levels. We assume that future information
levels are conditionally independent of previous treatment effect estimates given previous
information levels. Violations of this assumption can result in an inflation of the type I
error rate. [35] If the information level at a data look is unknown, it has to be estimated and
the respective critical value is calculated based on the estimated information level. The
information levels are functions of the exposure times, the rates, and the shape parameter.
While the exposure times at look k become known, the rates and the shape parameter
remain unknown and must be estimated from the available data. Let Iˆk be the plug-
in estimator of the information level Ik at data look k obtained through the maximum
likelihood estimators (βˆ1k, βˆ2k, φˆk). Then, the type I error rate pik allocated to data look
k is given by
pi1 = f
(
Iˆ1/Imax
)
,
pik = f
(
Iˆk/Imax
)
− f
(
Iˆk−1/Imax
)
, k = 2, 3, . . . , K − 1.
It is important to emphasize that the information level estimator Iˆk−1 calculated at the
previous data look is not updated at data look k. When the theoretical information
gain between looks k − 1 and k is small, it might occur that the estimated information
decreases, that is Iˆk < Iˆk−1. In this case, no type I error rate is allocated to data look k,
i.e., pik = 0 and the null hypothesis cannot be rejected at data look k. Moreover, at the
end of the trial, i.e., at data look K, the estimated information level IˆK usually differs
from the anticipated maximum information level Imax. Therefore, the remaining type I
error rate is allocated to data look K, i.e.,
piK = α− f
(
IˆK−1/Imax
)
.
When the type I error rate α is allocated based on information estimates, the allocated
rates still sum up to α. In addition to pik, the covariance matrix Σk of the canonical
joint distribution has to be estimated to calculate the critical value ck. The entries of
the covariance matrix (4) are estimated by plugging in the respective information level
estimators, with the estimator for the information level at data look k only using the data
available up to data look k.
The maximum likelihood estimators of the rates and the shape parameter are con-
sistent estimators. Since the Fisher information, the information levels, the information
level ratios, and the allocation of the type I error rate are continuous functions in the rates
and the shape parameter, the respective plug-in estimators are consistent estimators, too.
Thus, the discussed asymptotic considerations about the Wald test in group sequential
designs with negative binomial outcomes still hold.
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4 Planning aspects of group sequential designs
An important part of planning a clinical trial is to determine the sample size. An ade-
quately planned sample size assures that the trial is able to detect a relevant treatment
effect with high probability. In group sequential designs the sample size becomes a ran-
dom variable and the maximum information and the (information) time of the data looks
are fixed. Highlighting the specifics for the case of a negative binomial outcomes, in the
following we recapitulate the general approach for power and sample size planning in
group sequential designs. [2] We start with group sequential designs which only include
stopping for efficacy and conclude with designs additionally including non-binding futility
boundaries. Under the alternative H1, that is for θ < δ, the power of a group sequential
design for a given maximum number of looks K and a set of critical values c1, . . . , cK is
given by
Power = 1− Pθ (T1 > c1, . . . , TK > cK) . (5)
As stated in (2), under the alternative H1, the test statistic Tk can be approximated
by a normal distribution. Moreover, the vector of test statistics (T1, . . . , TK) can be
approximated by a multivariate normal distribution with mean vector
µ =
(√
I1 (log (θ)− log(δ)) , . . . ,
√
IK (log (θ)− log(δ))
)′
and covariance matrix as defined in (4). For calculating the power and the sample size,
the parameter under the alternative hypothesis H1 is fixed at θ = θ∗. However, the
information levels Ik (k = 1, . . . , K) of the data looks are unknown. In order to decide
about the placement of the data looks, it is convenient to express the information level
Ik as a fraction of the maximum information Imax, i.e., Ik = wkImax, k = 1, . . . , K, wk ∈
(0, 1]. The ratio wk is prespecified and denotes the information fraction at which the k-th
data look is conducted. Then, the mean vector and the covariance of the canonical joint
distribution can be simplified to only depend on the maximum information level, i.e., the
mean vector is given by
µ = (log(θ∗)− log(δ))
√
Imax (√w1, . . . ,√wK)′
and the (k1, k2)-th and (k2, k1)-th entry of the covariance matrix reduce to
√
wk1/wk2. The
maximum information level Imax is now the only missing variable in the power function
and the maximum information I(1−β)max required to obtain a prespecified power can be
calculated by solving (5). It is worth emphasizing that achieving the target power can
only be guaranteed if the data looks are performed when the observed information level
ratios reach the prespecified ratios wk, k = 1, . . . , K. If the information level ratios of
the data looks are changed during the conduct of the clinical trial while the maximum
information I(1−β)max remains unchanged, the actual power might differ from the target
power. Moreover, performing the data looks at prespecified information times requires
that the information is monitored. We revisit the issue of information monitoring in the
discussion. As of now, we discussed calculating the maximum information I(1−β)max required
to obtain a prespecified power in a clinical trial with a group sequential design and negative
binomial outcomes. Next, we focus on the actual sample size. The sample sizes n1 and
10
n2 required to obtain the power 1− β can be calculated using the maximum information
level I(1−β)max . Let κ = n2/n1 be the randomization ratio, tij = tijK the exposure times at
the end of the trial, and µ∗1, µ
∗
2 the rates under the alternative hypothesis H1. Then, the
sample size n1 required to obtain a power of 1− β is obtained by solving(∑n1
j=1
t1jµ∗1
1+φt1jµ∗1
) (∑κn1
j=1
t2jµ∗2
1+φt2jµ∗2
)
∑n1
j=1
t1jµ∗1
1+φt1jµ∗1
+
∑κn1
j=1
t2jµ∗2
1+φt2jµ∗2
= I(1−β)max .
This equation highlights that the sample size n1 can only be calculated with assumptions
on the exposure times tij . Common approaches include planning the study with a mini-
mum or in general an identical exposure time, i.e., tij = t. In the latter case the sample
size n1 is given by
n1 = I(1−β)max
(
µ1 + κµ2
tκµ1µ2
+ (1 + κ)φ
)
.
We conclude this section with a discussion of the planning of a group sequential design
which includes non-binding futility boundaries in addition to the efficacy boundaries.
Non-binding futility rules for group sequential designs are calculated such that the type
I error rate is still maintained if the non-binding futility rules are not applied. However,
non-binding futility rules can affect the power. In the following, we briefly outline the
calculation of the maximum information and non-binding futility boundaries such that
the power is achieved based on the error spending approach, see also Section 7 in Jennison
and Turnbull (2000). [2] In a group sequential design with non-binding futility, the efficacy
boundaries are calculated as in a group sequential design without futility stopping which
we discussed above. Let ck be the efficacy boundary and pik the allocated type I error rate
at data look k = 1, . . . , K. The power 1− β is set at the alternative θ = θ∗. For planning
purposes we prespecify the information fraction wk = Ik/Imax at data look k = 1, . . . , K.
Let g : [0,∞)→ [0, β] with g(0) = 0 and g(t) = β for t ≥ 1 be the type II error spending
function. Here, β denotes the target type II error rate, i.e., the target power is P = 1−β.
To determine the non-binding futility boundaries, the type II error rate β is allocated to
the different data looks using the type II error spending function:
ζ1 = g (I1/Imax) ,
ζk = g (Ik/Imax)− g (Ik−1/Imax) , k = 2, . . . , K.
Here, ζk denotes the type II error rate allocated to data look k. Then, the non-binding
futility boundaries dk (k = 1, . . . , K) and the maximum information level Imax to obtain
the type II error rate β are determined by solving the following system of equations
numerically:
ζk = Pθ∗ (c1 < T1 < d1, . . . , Tk ≥ dk) , k = 1, . . . , K,
cK = dK .
5 Simulation study
The theoretical considerations of group sequential designs with negative binomial out-
comes rely on the asymptotic normality of the Wald statistics and that the joint distribu-
tion of the Wald statistics from different data looks asymptotically follows the canonical
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joint distribution. Therefore, in this section we assess the operating characteristics of the
proposed group sequential design for negative binomial distributed outcomes for finite
sample sizes by means of Monte Carlo simulation studies. The operating characteristics
are the type I error rate, the power, the expected trial duration, the expected sample
size, and the expected information level. Particular emphasis is put on the potential ben-
efits of group sequential designs compared to fixed sample designs for negative binomial
outcomes. The type I error rate is assessed to study whether a group sequential design
inflates the type I error rate compared to a fixed sample design. Such an assessment is
necessary for asymptotic tests because the sample size at the interim analyses is in general
lower compared to the fixed sample design which can increase the type I error rate of a
test in the group sequential design compared to the fixed sample design. The choice of
simulation scenarios is motivated by the clinical trial examples discussed in Section 2.
The clinical trial examples result in two very different simulation setups. The annualized
rates in the scenarios motivated by the number of CUALs in relapsing-remitting multiple
sclerosis is about tenfold the annualized hospitalization rates in chronic heart failure with
preserved ejection fraction. The sample size in the clinical trial in multiple sclerosis is
substantially smaller than the sample size in the heart failure trial (around 100 versus
around 1000 patients per arm). In the scenarios motivated by the multiple sclerosis trial
a fixed exposure time of 6 months at the end of study is assumed. In the scenarios moti-
vated by the heart failure trial patients are uniformly recruited over a period of 15 months
and followed until the study ends after 48 months, i.e., the exposure times vary between
33 and 48 months. For the simulations, we select the patients’ recruitment times in a
deterministic manner. The shape parameter is similar in the two motivating examples
with φ = 2, 3, 4 for the multiple sclerosis scenarios and φ = 2, 3, 4, 5 for the chronic heart
failure scenarios. It is important to note that even though the shape parameters are sim-
ilar in the two sets of scenarios, the variances and the overdispersion of the counts are
very different. For negative binomial outcomes the variance is tµ(1 + φtµ) and the index
of overdispersion D, that is the ratio of the variance and the expected value, is equal
to D = 1 + tµφ. While the shape parameter is similar in the two sets of scenarios, the
rates are not similar. Therefore, the variance and the overdispersion in the scenarios for
clinical trials in multiple sclerosis are much larger than in the scenarios for clinical trials
in chronic heart failure. The simulation study is conducted for a test of superiority, i.e.
H0 : µ1/µ2 ≥ δ = 1. The one-sided significance level is α = 0.025 and the target power
under the alternative θ = θ∗ is 1− β = 0.8, 0.9. The parameters for the simulation study
are listed in Table 3.
The data looks are performed at prespecified calendar times at which an information level
of Ik = kImax/K (k = 1, . . . , K) is expected based on the parameters of the respective
scenario. The observed information level Iˆk at which the data look is performed might
differ from the preplanned information level Ik. The type I error rate allocation and
the critical value calculation at each data look k = 1, . . . , K are performed based on the
observed information level Iˆk. Performing the simulations with data looks at prespecified
calendar times reduces the computational effort because no information monitoring is re-
quired. Moreover, since the type I error is allocated and the critical values are calculated
based on the observed information level, any potential effect due to estimating the infor-
mation levels is still incorporated. In the simulations, the shape parameter φ is estimated
as it would be in practical applications.
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Table 3: Scenarios considered in the simulation study motivated by the clinical trial
examples from Section 2.
Multiple sclerosis Heart failure
One-sided significance level α 0.025 0.025
Superiority margin δ 1 1
Shape parameter φ 2, 3, 4 2, 3, 4, 5
Data looks K 2, 3 2, 3, 5
Individual follow-up [years] 0.5 2.75–4
Recruitment period [years] 1.5 1.25
Study duration [years] 2 4
Simulations under H0
Maximum sample sizes n1 = n2 50, 80, . . . , 230 800, 1100, 1400
Annualized rates µ1 = µ2 6, 8, 10 0.08, 0.1, 0.12, 0.14
Simulations under H1
Annualized rate µ2 8.4 0.125
Rate ratio θ∗ = µ1/µ2 0.5, 0.7 0.7, 0.8
Target power 1− β 0.8, 0.9 0.8, 0.9
We consider group sequential designs with the error spending functions which give
critical values similar to the ones for Pocock’s test and O’Brien & Fleming’s test, [34]
respectively, i.e.,
fP (x) = min {α log (1 + (e− 1)x) , α} ,
fOF (x) = min
{
2
(
1− Φ
(
qα/2√
x
))
, α
}
.
Here, e = exp(1) denotes Euler’s number and qα denotes the α-quantile of a standard
normal distribution. We present the simulation results for the scenarios motivated by the
number of heart failure hospitalizations and the results for the scenarios motivated by the
number of lesions separately, starting with the results for the heart failure hospitalization
scenarios.
5.1 Heart failure hospitalizations
In the following we study the performance of the proposed group sequential procedure
for scenarios motivated by the number of heart failure hospitalizations in clinical trials
for heart failure patients with preserved ejection fraction. The scenarios are characterized
by large sample sizes of around 1000 patients per arm, small annualized event rates of
around 0.1, and unequal exposure times of several years. The first part of the Monte
Carlo simulation study focuses on the assessment of the type I error rate. We consider
the scenarios listed in Table 3 which cover a range of shape parameters, rates, sample sizes,
and number of data looks in the group sequential design. In Figure 1 the simulated type
I error rates of the Wald test for the fixed sample design and the two group sequential
designs are displayed. Each dot represents the simulated type I error rate of a single
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scenario based on 50 000 Monte Carlo replications. In each frame of the 1 × 3 grid the
type I error rate is plotted against the sample size n1 = n2 for a specific design. For the
group sequential designs n1 = n2 refers to the maximum sample size if the trial is not
stopped early. For the fixed sample design fewer scenarios exist because the number of
data looks is not varied, i.e., the data is only analyzed at the end of the trial. Figure 1
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Figure 1: Type I error rate of the Wald test for negative binomial outcomes in the fixed
sample design and in group sequential designs with O’Brien-Fleming-type and Pocock-
type error spending functions. The black line depicts the nominal one-sided type I error
rate of α = 0.025. The horizontal grey lines mark α± 2SE with SE the simulation error
at a simulated type I error rate of 0.025.
shows that the Wald test for the group sequential design controls the type I error rate
and that no practically relevant type I error inflation compared to the Wald test in the
fixed sample design is detectable. To further assure that the simulation error does not
mask a type I error inflation, we performed additional simulations for the scenario with
rates µ1 = µ2 = 0.14, a shape parameter of φ = 5, a maximum of K = 5 data looks, and
sample sizes n1 = n2 = 800, . . . , 1600. In this scenario both the overdispersion and the
maximum number of data looks are large which is when one would expect a type I error
inflation. The results are reported in Section 1 of the supplemental material and show
type I error rates of around 0.0253 for the fixed sample design and the group sequential
design with O’Brien-Fleming-type error spending function. The type I error rates of the
group sequential design with Pocock-type spending function are about 0.02507. Due to
the large number of 400 000 Monte Carlo replications, this assures that no practically
relevant type I error inflations are present.
Regarding the power, the required maximum information and sample size for a power
1− β are calculated using the planning approach proposed in the previous section under
the assumption of a four year study and an uniform recruitment during an accrual period
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of 1.25 years. The simulation results are listed in Table 4. Table 4 shows that the
sample size calculations described in Section 4 are accurate in the sense that they result
in the test having the target power. In particular, recalculating the critical values at
the time of the analysis does not affect the power as long as the information time of the
analysis corresponds to the information time considered during the planning phase. The
group sequential designs reduce the expected information compared to a fixed sample
design. Comparing the two group sequential designs, the design with a Pocock-type error
spending function results in the larger reduction of the expected information and in the
larger probability for rejecting early than the design with O’Brien-Fleming-type error
spending function. However, the group sequential designs required a larger maximum
information and a larger maximum sample size compared to the fixed design.
5.2 MRI lesions in relapsing multiple sclerosis
The simulation scenarios in the previous section were characterized by trial sizes in the
thousands, small event rates of less than one event per patient and year, and unequal
follow-up times of multiple years. In contrast, the simulation scenarios in this section are
characterized by event rates of around one event per month, equal exposure times of 6
months per patient, and clinical trial sizes of around 100. The scenarios are motivated
by MRI lesion counts in clinical trials in multiple sclerosis. As in the last paragraph, the
results concerning the type I error rate of the Wald test for the fixed sample design and
the group sequential design are presented first, followed by the discussion of the power
related simulation results. Figure 2 shows the simulated type I error rates. For each rate
25 000 Monte Carlo replications were performed.
Figure 2 shows that even in the fixed sample design the Wald test does not control the
type I error rate, which is in agreement with previously published results. [36] Moreover,
the type I error rate of the Wald test in the group sequential designs is inflated compared
to the Wald test in the fixed sample design. The type I error inflation is more extreme
in the group sequential design with the Pocock-type error spending function. The type
I error rate of the Wald test in group sequential designs is inflated because in group
sequential designs the null hypothesis is tested several times during data look with small
sample sizes and the smaller the sample size, the larger the type I error inflation of the
Wald test. However, for every design the type I error rate of the respective Wald test
converges to the target type I error rate as the maximum sample size increases.
As in Section 5.1, the maximum information levels and the sample sizes for the power
related simulation study are calculated such that the respective design is powered to
the prespecified level 1 − β. The results of the simulation study are listed in Table
5. Table 5 shows that the approach for planning group sequential designs presented in
Section 4 already works for maximum sample sizes of around 80 patients per treatment
arm although the planning method relies on asymptotic considerations. However, it is
important to keep in mind that the type I error rate is not controlled for smaller sample
sizes. The relationship between the maximum information for the fixed sample design
and for the group sequential design is similar to the scenarios presented in Table 4.
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Figure 2: Type I error rate of the Wald test for negative binomial outcomes in the fixed
sample design and in group sequential designs with O’Brien-Fleming-type and Pocock-
type error spending functions. The black line depicts the nominal type I error rate of
α = 0.025. The horizontal grey lines mark α ± 2SE with SE the simulation error at a
simulated type I error rate of 0.025.
6 Adjustments for small sample sizes
The type I error rate of the proposed Wald test for group sequential designs is inflated in
the case of small sample sizes as illustrated in Figure 2. The type I error rate inflation is the
result of a mismatch between the distribution of the Wald statistic for negative binomial
outcomes and the assumed multivariate normal distribution when calculating the critical
values. By means of simulations, it can be observed that the distribution of the Wald
statistic for small sample sizes has heavier tails than a normal distribution. Thus, the
type I error rate inflation of the Wald test can be reduced by adjusting the Wald statistic
such that its distribution is approximated more closely by a normal distribution or by
adjusting the calculation of the critical values. In this section we suggest modifications of
the Wald statistic and the critical values which reduce the type I error rate inflation of the
Wald test for group sequential designs with negative binomial outcomes. It is important
to emphasize that while we discuss adjustments to the Wald statistics and adjustments to
the critical values in separate subsections, both adjustment can be applied simultaneously
to the initially proposed Wald test for group sequential designs.
6.1 Adjusting the Wald statistic
To obtain a Wald statistic which is approximated more closely by a normal distribution,
we propose to estimate the variance in the Wald statistic restricted to the parameter space
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of the null hypothesis. This has already been shown to reduce the type I error inflation
in several designs, among them also designs with negative binomial outcomes. [37–39] In
detail, in the context of group sequential designs the variance estimator for the Wald
statistic Tk at look k is an estimator for the information level Ik. The restricted variance
estimator, i.e., an information level estimator restricted to the null hypothesis, is obtained
by plugging in the restricted maximum likelihood estimators of the rates and the shape
parameter into (1). With L(β1, β2, φ|Yijk, j = 1, . . . , ni, i = 1, 2) the likelihood function
at look k, the maximum likelihood estimators restricted to the null hypothesis H0 are
defined by
(βˆ(R)1k , βˆ
(R)
2k , φˆ
(R)
1k ) = argmax
β1−β2≥log(δ)
L(β1, β2, φ|Yijk, j = 1, . . . , ni, i = 1, 2).
The restricted maximum likelihood estimators and the restricted information level esti-
mator are consistent estimators under the null hypothesis and, thus, the results about
the asymptotic normality of the joint distribution of the Wald statistics under the null
hypothesis still hold.
6.2 Modifying the critical values
To limit the type I error rate inflation in the case of small sample sizes, we discuss several
approaches for modifying the critical values.
Pocock modification Pocock (1977) suggested to calculate the critical values for a
group sequential design with Student’s t-test by transforming the critical values from the
normal distribution with the inverse cumulative distribution function of a t-distribution,
that is the distribution of the test statistic. [40] In general, the idea is to obtain the critical
value for data look k through the transformation F−1(Φ(ck)), where ck is the critical value
obtained through the canonical joint distribution, Φ(·) the cumulative distribution func-
tion of the standard normal distribution, and F−1(·) the inverse cumulative distribution
function of the distribution of the test statistic. [2]
The finite sample size distribution of the Wald statistic Tk is unknown. As an approx-
imation, F (·) can be chosen as the cumulative distribution of Student’s t-distribution,
because Student’s t-distribution has heavier tails than a normal distribution and approxi-
mates the distribution of the Wald statistics better than the normal distribution for small
sample sizes. [41] Alternatively, F (·) can be the cumulative distribution function of a re-
sampling distribution. In the following we outline the use of the permutation distribution
of the Wald statistics for calculating the critical values. For this purpose, let (τ(i))i≤n
be a random variable which is uniformly distributed on the group Sn, i.e., the group of
all permutations of the vector (1, 2, . . . , n), and let P˜ be the respective probability mea-
sure. Let Yk = (Y11k, . . . , Y2n2k) be the vector of the random variables at data look k
and let τ(Yk) denote the randomly permuted vector Yk. The probability measure P˜ is
independent of the vector Yk. With T (Yk) the Wald statistic as a function of the random
variables, the permutation statistic is defined by results of the mapping
(τ(i))i≤n 7→ T (τ(Yk))|Yk.
Then, the permutation distribution refers to the distribution of the permutation statistic
T (τ(Yk))|Yk with respect to the probability measure P˜. For the Pocock modification of
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the critical values in group sequential testing, we propose to choose F (·) as the cumulative
distribution function of the permutation distribution.
Multivariate t-distribution Since the Wald statistic for negative binomial outcomes
has heavier tails than the normal distribution but is still symmetric around zero under
the null hypothesis, it seems natural to approximate the joint distribution of the Wald
statistics T1, . . . , TK by a multivariate Student’s t-distribution. This means that the crit-
ical value ck for the Wald test at look k is calculated by solving (3) under the assumption
that the joint distribution of test statistics T1, . . . , Tk follows a multivariate Student’s
t-distribution. The multivariate Student’s t-distribution has a mean vector 0, the same
k×k-dimensional covariance matrix Σ as defined in (4), and ν degrees of freedom. There
is a variety of potential choices for the number of degrees of freedom ν of the multivariate
Student’s t-distribution. In the context of testing treatment differences in nested sub-
groups, which are statistically the same problem as testing in group sequential designs as
illustrated by Spiessens and Debois (2010). [43] Placzek and Friede (2017) [42] proposed a
conservative and a liberal choice for the degrees of freedom of the multivariate Student’s
t-distribution. The conservative choice is to use the degrees of freedom of the smallest sub
population and the liberal choice is to use the degrees of freedom of the full population.
Transferred to group sequential designs, the conservative choice for the degrees of freedom
are the degrees of freedom of the first data look and the liberal choice are the (planned)
degrees of freedom of the last data look. As noted by Graf et al. (2017) the Pocock
approach with F (·) the cumulative distribution function of Student’s t-distribution and
calculating the critical values through a multivariate Student’s t-distribution do not result
in the same critical values. [44]
6.3 Simulation study
In this subsection we assess the performance of the proposed adjustments to the Wald
statistics and the critical values in group sequential designs with negative binomial out-
comes. Since both adjustments can be applied simultaneously or separately, there are
several group sequential testing procedures worth investigating. We restrict our presenta-
tion of the results to the two procedures which actually resulted in an appropriate control
of the type I error rate. The first procedure tests based on the Wald statistic with the
variance estimation restricted to the null hypothesis and the critical values are calculated
using the multivariate t-distribution with the degrees of freedom the number of subjects
recruited at the first data look. The second procedure also tests the null hypothesis using
the Wald statistic with the variance estimation restricted to the null hypothesis and its
critical values are based on Pocock’s modification with the permutation distribution as
the cumulative distribution function F (·). The number of permutations of a vector with
length n is too large to exactly determine the permutation distribution. Instead, for a
given vector Yk, 15 000 random permutations of the vector are generated and for each of
the resulting permuted vector the test statistic T (τ(Yk)) is calculated. For calculating
the critical value, the resulting empirical cumulative distribution function Fˆ (·) is utilized.
Since the second procedure requires intensive computations, we only vary the sample size
and keep the remaining parameters fix, i.e., we choose annualized rates µ1 = µ2 = 10,
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shape parameter φ = 4, number of data looks K = 3, and the other parameters as listed
in Table 3. This scenario is characterized by a large overdispersion which is associated
with a large type I error inflation of our initially proposed group sequential procedure.
Therefore, the procedure which controls the type I error rate for the considered scenario
also control the type I error rate for scenarios in which the initially proposed procedure
has a smaller type I error inflation. The results are illustrated in Figure 3. Figure 3 shows
O’Brien & Fleming Pocock
50 80 110 140 170 50 80 110 140 170
0.025
0.030
0.035
0.040
Maximum sample size n1=n2
Ty
pe
 I 
er
ro
r r
a
te
Multivariate t−distribution Permutation Standard
Figure 3: Type I error rate of the Wald test with and without modifications for negative
binomial outcomes in group sequential designs with O’Brien-Fleming-type and Pocock-
type error spending function. The black line depicts the planned one-sided type I error
rate of α = 0.025. The horizontal grey lines mark α± 2SE with SE the simulation error
at a simulated type I error rate of 0.025.
that both modifications of the group sequential procedure yield type I error rates close
to the target level α = 0.025. For the O’Brien-Fleming-type error spending function,
the modification based on the multivariate Student’s t-distribution results in type I error
rates closer to the nominal level than the procedure based on Pocock’s modification with
the permutation distribution as the cumulative distribution function. For the Pocock-
type spending function, these results are reversed, i.e., the procedure based on Pocock’s
modification performs better.
Noteworthy, the group sequential procedure based on the Pocock’s modification with the
permutation distribution is not to be confused with the actual group sequential permuta-
tion test. The group sequential permutation test calculates the critical values as outlined
in Section 3 based on a joint distribution obtained through resampling instead of based on
a multivariate normal distribution. In more detail, at data look k˜ the joint permutation
distribution is obtained by permuting the treatment indicators and then calculating the
test statistics (T1, . . . , Tk˜) from different data looks. In practice, the number of permu-
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tations is too large to actually calculate the test statistics (T1, . . . , Tk˜) for all available
permutations. Thus, the permutation distribution is approximated by calculating the
test statistics for a set of random permutations. A group sequential permutation test will
control the type I error rate but is also computationally more expensive than Pocock’s
modification with the permutation distribution. While this is not a problem when ana-
lyzing a single trial, this can be an issue when evaluating permutation tests in simulation
studies, even if efficient methods for assessing permutation tests, see Jennison (1992), [45]
are used.
7 Clinical trial examples revisited
In this section we study the effects of rejecting early in a group sequential design. We
illustrate how an early rejection effects the sample size, study duration, information level,
and total follow-up years. The parameters used in our illustration are motivated by the
clinical trial examples from Section 2. The conclusions drawn from the examples cannot
be generalized and are specific to the design parameters.
7.1 Chronic heart failure
We consider a clinical trial which is planned with a group sequential design with O’Brien-
Fleming-type error spending function and one interim analysis at 0.5Imax, powered to
80% for the alternative θ∗ = 0.7 under the assumption of the nuisance parameters φ = 5
and µ2 = 0.125. Moreover, the clinical trial is planned for a duration of four years, with
an accrual period of 15 months, and a planned recruitment of 1956 patients (in total).
The recruitment is assumed to be uniform in the accrual period. Let τ be the time since
recruiting the first patient and let Iτ , nτ , and tτ be the information level, the total sample
size, and the total follow-up years at time τ . Additionally, let Imax, nmax, and tmax be
the respective parameter at the end of study if the study is not stopped early for efficacy.
In Figure 4 the proportions Iτ/Imax, nτ/nmax, and tτ/tmax are plotted against the time
τ . Figure 4 highlights that the information level, the sample size, and the total follow-up
years are not linear in the study duration τ . Moreover, at the end of the accrual period,
that is after τ = 1.25 years, only 36% of the maximum information level Imax has been
accumulated. Thus, in this clinical trial with a group sequential design where the interim
analysis is performed at an information time of 0.5Imax, the number of patients would
not be lowered if the trial is stopped early. The benefit of an early stopping is shortening
the clinical trial by over two years. Moreover, Figure 4 depicts that the longer the trial
continues, the smaller the information gain per time unit about the unknown treatment
effect.
7.2 Relapsing-remitting multiple sclerosis
Motivated by the clinical trial in multiple sclerosis discussed in Section 2, in the following,
the focus is on a clinical trial where the accrual period is 18 months and each patient has
an identical follow-up time of 6 months. The patients are recruited uniformly throughout
the accrual period. The clinical trial has a group sequential design with O’Brien-Fleming-
type error spending function with one interim analysis. In total, 220 patients are included
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Figure 4: Proportions Iτ/Imax, nτ/nmax, and tτ/tmax versus the study time τ . The dashed
grey line marks a linear increase in the study time τ . For the scenario considered, see
text.
into the trial which corresponds to a power of 80% for a rate ratio θ∗ = 0.5 and nuisance
parameters φ = 3 and µ2 = 8.4. The sample size of a fixed sample design with the
same parameters is identical. In Figure 5 the proportions Iτ/Imax, nτ/nmax, and tτ/tmax
are plotted against the study time τ . Figure 5 highlights that in the studied setting of
identical follow-up times of six months much can be gained with respect to sample size
reduction by conducting a group sequential design instead of a fixed sample design. For
example, if the trial is stopped after an interim analysis conducted at an information time
of Iτ/Imax = 0.5, which is achieved at τ = 0.84 years, the sample size would be reduced
from 220 to 122 patients. Compared to the example of a clinical trial in heart failure with
multiple years of individual follow-up times, the potential for reducing the trial duration
is limited since the trial runs for two years and recruiting is planned for 1.5 years.
8 Discussion and outlook
In this manuscript we proposed a Wald test based on maximum likelihood estimates
for analyzing group sequential designs with negative binomial outcomes. The proposed
testing procedure asymptotically follows the canonical joint distribution, that is the in-
crements are asymptotically independent. In a simulation study with scenarios motivated
by clinical trials in chronic heart failure and relapsing multiple sclerosis we assessed the
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Figure 5: Proportions Iτ/Imax, nτ/nmax, and tτ/tmax versus the study time τ in years.
The dashed grey line marks a linear increase of the proportions in the study time τ . For
the scenario considered, see text.
finite sample size characteristics of the proposed testing procedure. The simulation study
shows that the testing procedure controls the type I error rate for large sample sizes but
also revealed that the testing procedure does not control the type I error rate for small
sample sizes and high overdispersion. The magnitude of the type I error inflation in the
group sequential design compared to the fixed sample design depends on the number of
data looks, the sample size, the overdispersion, and on the error spending function. In
Section 6 we suggested modifications of the proposed Wald test which resulted in type I
error rates closer to the nominal level. From the results of the simulation study we can
also conclude that the planning methodology already performs well for small maximum
sample sizes of around 80 patients per arm even for large overdispersion indices between
6 and 20. The proposed methodology for planning group sequential designs with negative
binomial outcomes is based on the theory of the canonical joint distribution. However,
the information level for negative binomial outcomes depends on the distribution param-
eters, i.e., the rates and the shape parameter, the sample size, but also on the exposure
times of the individual patients. We discussed in detail the resulting flexibility for group
sequential designs with negative binomial outcomes in Section 7.
Group sequential designs with negative binomial outcomes are so far not implemented
in any software package for group sequential designs. Our new R package gscounts imple-
ments the methodology for planning and analyzing group sequential design with negative
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binomial outcomes as described in this manuscript. [46] The implementation includes the
option for binding and non-binding futility stopping. Additionally, the R package gscounts
also contains functions for planning fixed sample designs with negative binomial outcomes.
In this article, we considered group sequential designs, where stopping for success is
based on a statistical significance test. In early phase trials, often double criteria for
stopping for success are used, which are based on both statistical significance and clini-
cal relevance. [47,48] Group sequential designs using such double criteria are described by
Gsponer et al., which also discuss a multiple sclerosis example with negative binomially
distributed lesion count data. [49]
The negative binomial model is a common choice to model MRI lesions in relapsing-
remitting multiple sclerosis as discussed in Section 2. However, since the number of MRI
lesions is gathered based on MRIs which are performed every couple of weeks or months
during a clinical trial, the true time points at which new or enlarging MRI lesions occur
is unknown. Instead, generally only the time point at which the MRI was performed and
how many new or enlarging lesions were counted are known. Asendorf et al. proposed
a negative binomial integrated value autoregressive process for modeling MRI lesions in
this situation. [50] As an extension of the methods presented in this manuscript, group
sequential designs could be studied for negative binomial integrated value autoregressive
processes.
A covariate is typically included into the analysis of clinical trials if the covariate has a
strong impact on the primary outcome. The aim when including a covariate is to minimize
the bias and maximize the efficiency of the statistical analysis. [51] Covariate adjustment
in group sequential clinical trials has already been studied for normal linear models. [33]
The natural extension of the negative binomial distribution considered in this manuscript
to a model with covariates is the negative binomial regression model. [30]
When the count data cannot be modeled with a parameteric distribution often quasi-
Poisson models are applied. In quasi-Poisson models, the rates are estimated with a
method of moments estimator. [52] Test statistics based on these method of moments esti-
mators do in general not fulfill the independent increment assumption. Thus, additional
methodological work is required to extend the already existing nonparametric and semi-
parametric methods for group sequential designs with recurrent events by methods for
the the quasi-Poisson model.
In the simulation study presented in this manuscript, the data looks were performed
at prespecified calendar times which in turn were determined based on the true param-
eters. In practice the information on the nuisance parameters and the accrual rate are
often not reliable enough to accurately determine the calendar time at which a certain
information level is attained prior to the trial. Therefore, clinical trials are monitored and
the time point of a data look is often selected based on the available data. Monitoring
procedures and the potential effect on the type I error rate have already been studied
extensively. [35,53,54] As an alternative to classical frequentist procedures a Bayesian ap-
proach has been suggested. [55] In future research procedures for monitoring group sequen-
tial designs with negative binomial outcomes should be developed and their operating
characteristics be assessed. In particular, if the information of a trial is monitored and
the trial is stopped at a prespecified maximum information, design aspects such as the
sample size and study duration can or must be adaptable. Thus, part of the development
of monitoring procedures must be the assessment of design adaptation rules; for the sam-
23
ple size existing approaches can be applied. [56,57]
Testing nested subgroups is statistically the same problem as testing in a group se-
quential design as illustrated by Spiessens and Debois. [43] Therefore, the results presented
in this manuscript can also be applied to clinical trials with nested subgroups and are
relevant to precision and personalized medicine.
A Maximum likelihood estimators
In this appendix we show that at data look k = 2, . . . , K the negative binomially dis-
tributed random variables Yijk (j = 1, . . . , ni, i = 1, 2) are sufficient for (β1, β2, φ), i.e.,
that the distribution of Yij1, . . . , Yij(k−1)|Yijk does not depend on the rates or the shape
parameter. Therefore, the maximum likelihood estimators for the rates and the shape pa-
rameter at data look k only depends on the random variables Yijk (j = 1, . . . , ni, i = 1, 2)
and not on the counts from previous data looks.
For independently Poisson distributed random variables Xi ∼ Pois(λi) with i =
1, . . . , n, conditioned on their sum, the vector of Poisson random variables X1, . . . , Xn
follows a multinomial distribution:
X1, . . . , Xn|X· ∼ Multinom (n,p) .
Here, X· =
n∑
i=1
Xi is the sum of random variables and the i-th entry of vector p ∈ Rn
is defined by pi = λi/λ· with λ· the sum of the rates λi (i = 1, . . . , n). In the following
we use this property about independently Poisson distributed random variables to show
that at data look k = 2, . . . , K the random variables Yijk (j = 1, . . . , ni, i = 1, 2) are
sufficient for (β1, β2, φ). Conditioned on the subject specific rate λij, the increments
Yij1, Yij2 − Yij1, . . . , Yijk − Yij(k−1) are independent and Poisson distributed. With the
above property for independent Poisson distributions, it follows that conditioned on the
rate λij and on the random variable Yijk, the vector of increments follows a multinomial
distribution, i.e.,
Yij1, Yij2 − Yij1, . . . , Yijk − Yij(k−1)
∣∣∣∣Yijk, λij ∼ Multinom (n,p) ,
p =
(
tij1
tijk
,
tij2 − tij1
tijk
, . . . ,
tijk − tij(k−1)
tijk
)
.
From the conditional joint distribution of the increments, it follows that the distribution
of Yij1, . . . , Yij(k−1)|Yijk, λij does not depend on λij and therefore it also does not depend
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on the parameters (β1, β2, φ):
P
(
Yij1 = yij1, . . . , Yij(k−1) = yij(k−1)|Yijk = yijk, λij
)
=P
(
Yij1 = yij1, Yij2 − Yij1 = yij2 − yij1, . . . ,
Yijk − Yij(k−1) = yijk − yij(k−1)|Yijk = yijk, λij
)
=
yijk!
yij1! · (yij2 − yij1)! · . . . · (yijk − yij(k−1))!
×
(
tij1
tijk
)yij1 (tij2 − tij1
tijk
)yij2−yij1
. . .
(
tijk − tij(k−1)
tijk
)yijk−yij(k−1)
.
Since the distribution of Yij1, . . . , Yij(k−1)|Yijk, λij is independent of the subject specific
event rate λij , the marginal distribution Yij1, . . . , Yij(k−1)|Yijk is also independent of λij.
This makes the random variable Yijk a sufficient statistic for the parameters (β1, β2, φ) at
data look k.
Next, we outline the maximum likelihood estimators for the parameters (β1, β2, φ). For
the sake of readability, we omit the third index k in all your notations. The maximum
likelihood estimators (βˆ1, βˆ2, φˆ) for the log-rates and the shape parameter are the solutions
to the following equations [30]
n1∑
j=1
Y1j − t1j exp(β1)
1 + φt1j exp(β1)
= 0,
n2∑
j=1
Y2j − t2j exp(β2)
1 + φt2j exp(β2)
= 0,
2∑
i=1
ni∑
j=1

−
Yij−1∑
l=0
(
1
φ+ lφ2
)
+
Yij
φ
+
log(1 + φtij exp(βi))
φ2
−(Yijφ+ 1)tij exp(βi)
φ+ φ2tij exp(βi)
}
= 0.
The solutions to those equations can be calculated using the multivariate Newton-Raphson
algorithm. The maximum likelihood estimator of the rate µi is then given by µˆi = exp(βˆi).
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Table 4: Results of power related simulations for scenarios motivated by heart failure hospitalizations in chronic heart failure.
Fix OF Pocock
1− β θ∗ φ K Ifix n1 Power Imax n1 Power P(stop early) E[I] Imax n1 Power P(stop early) E[I]
0.8 0.70 2 2 61.74 604 0.8040 61.94 606 0.8021 0.1901 57.28 69.30 678 0.8072 0.5944 52.59
0.8 0.70 2 3 61.74 604 0.8011 62.45 611 0.7984 0.5190 53.66 72.26 707 0.8033 0.7453 50.70
0.8 0.70 2 5 61.74 604 0.8037 63.27 619 0.7954 0.7186 51.10 74.82 732 0.8004 0.9077 49.35
0.8 0.70 5 2 61.71 975 0.7978 61.90 978 0.7996 0.1915 57.25 69.25 1094 0.8014 0.5940 52.77
0.8 0.70 5 3 61.71 975 0.8011 62.47 987 0.8000 0.5220 53.57 72.22 1141 0.8002 0.7513 50.59
0.8 0.70 5 5 61.71 975 0.8000 63.23 999 0.8004 0.7223 51.11 74.82 1182 0.7965 0.9170 49.35
0.8 0.80 2 2 157.59 1475 0.8008 158.23 1481 0.8027 0.1977 145.73 176.93 1656 0.8002 0.5963 134.70
0.8 0.80 2 3 157.59 1475 0.7990 159.62 1494 0.7983 0.5224 136.69 184.52 1727 0.8017 0.7555 128.96
0.8 0.80 2 5 157.59 1475 0.8030 161.55 1512 0.8009 0.7168 130.18 191.14 1789 0.8001 0.9108 125.01
0.8 0.80 5 2 157.61 2423 0.8014 158.19 2432 0.7963 0.2043 145.49 176.93 2720 0.8049 0.6019 134.04
0.8 0.80 5 3 157.61 2423 0.8028 159.63 2454 0.7996 0.5166 136.89 184.47 2836 0.8006 0.7577 129.00
0.8 0.80 5 5 157.61 2423 0.7957 161.51 2483 0.7982 0.7283 130.02 191.17 2939 0.7977 0.9204 125.75
0.9 0.70 2 2 82.59 808 0.9009 82.89 811 0.9042 0.2691 72.82 91.79 898 0.9036 0.6676 64.07
0.9 0.70 2 3 82.59 808 0.8994 83.61 818 0.9038 0.6231 67.25 95.36 933 0.9004 0.8162 59.50
0.9 0.70 2 5 82.59 808 0.8994 84.53 827 0.9023 0.8887 62.84 98.53 964 0.8995 0.9893 56.54
0.9 0.70 5 2 82.60 1305 0.9009 82.86 1309 0.8997 0.2795 72.49 91.78 1450 0.9015 0.6751 63.83
0.9 0.70 5 3 82.60 1305 0.9024 83.55 1320 0.9011 0.6269 67.13 95.32 1506 0.8993 0.8096 59.48
0.9 0.70 5 5 82.60 1305 0.8987 84.50 1335 0.8999 0.8820 62.97 98.49 1556 0.8996 0.9907 56.35
0.9 0.80 2 2 211.01 1975 0.9033 211.76 1982 0.9008 0.2778 185.36 234.41 2194 0.9016 0.6715 163.41
0.9 0.80 2 3 211.01 1975 0.8995 213.47 1998 0.9024 0.6232 171.28 243.60 2280 0.8988 0.8139 152.22
0.9 0.80 2 5 211.01 1975 0.8976 215.93 2021 0.8973 0.8941 160.76 251.61 2355 0.8989 0.9781 144.83
0.9 0.80 5 2 211.01 3244 0.8992 211.73 3255 0.8992 0.2772 185.42 234.43 3604 0.9021 0.6722 163.38
0.9 0.80 5 3 211.01 3244 0.8989 213.55 3283 0.9035 0.6188 171.73 243.54 3744 0.8994 0.8124 152.59
0.9 0.80 5 5 211.01 3244 0.9021 215.89 3319 0.9013 0.8893 160.23 251.60 3868 0.9016 0.9839 143.82
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Table 5: Results of power related simulations for scenarios motivated by lesion counts in multiple sclerosis.
Fix OF Pocock
1− β θ∗ φ K Ifix n1 Power Imax n1 Power P(stop early) E[I] Imax n1 Power P(stop early) E[I]
0.8 0.50 2 2 16.33 77 0.8002 16.33 77 0.8043 0.2589 15.04 18.24 86 0.8057 0.6032 14.18
0.8 0.50 2 3 16.33 77 0.8050 16.55 78 0.8034 0.5420 14.27 19.09 90 0.8052 0.7638 13.49
0.8 0.50 3 2 16.38 110 0.7989 16.38 110 0.8047 0.2413 15.08 18.32 123 0.8067 0.6069 14.13
0.8 0.50 3 3 16.38 110 0.7983 16.53 111 0.8017 0.5455 14.16 19.06 128 0.8049 0.7577 13.44
0.8 0.70 2 2 61.60 282 0.8004 62.03 284 0.8009 0.2155 57.09 69.24 317 0.8029 0.5949 53.08
0.8 0.70 2 3 61.60 282 0.8019 62.47 286 0.8017 0.5309 53.43 72.30 331 0.8018 0.7556 50.73
0.8 0.70 3 2 61.72 406 0.8012 61.87 407 0.8002 0.2149 56.85 69.32 456 0.8057 0.5998 52.85
0.8 0.70 3 3 61.72 406 0.7946 62.48 411 0.8034 0.5258 53.42 72.21 475 0.7970 0.7553 50.79
0.9 0.50 2 2 21.85 103 0.9010 21.85 103 0.9003 0.3142 19.15 24.39 115 0.9046 0.6816 17.23
0.9 0.50 2 3 21.85 103 0.9012 22.06 104 0.8994 0.6260 17.81 25.24 119 0.9030 0.8234 15.90
0.9 0.50 3 2 21.89 147 0.8999 21.89 147 0.9052 0.3066 19.17 24.28 163 0.9031 0.6739 17.16
0.9 0.50 3 3 21.89 147 0.9028 22.19 149 0.9035 0.6293 17.83 25.17 169 0.9008 0.8194 15.83
0.9 0.70 2 2 82.56 378 0.8996 82.78 379 0.8996 0.2890 72.42 91.74 420 0.9001 0.6699 64.44
0.9 0.70 2 3 82.56 378 0.9017 83.66 383 0.9007 0.6241 67.18 95.23 436 0.9038 0.8177 59.42
0.9 0.70 3 2 82.54 543 0.9004 82.85 545 0.9014 0.2895 72.30 91.82 604 0.9019 0.6729 64.25
0.9 0.70 3 3 82.54 543 0.8982 83.61 550 0.9039 0.6244 67.02 95.31 627 0.9012 0.8130 59.53
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